TCDA - Heron's Cinvanti Progress And Other News: The Good Bad And Ugly Of Biopharma
Heron Therapeutics Advances Phase 2 Study of CINVANTI
Heron Therapeutics Inc. (HRTX) announced that it has started its Phase 2 clinical study of CINVANTI. The company has started the trial after receiving a go-ahead from the FDA for its Investigational New Drug application for the drug candidate for treating COVID-19. The drug candidate is being tested on early hospitalized patients with COVID-19.
GUARDS-1 is a randomized, placebo-controlled, double-blinded study. It is also known as HTX-019-202. The study aims to evaluate the efficacy and safety of adding daily dosing of CINVANTI to standard of